Testosterone Science

FDA, Regulation and Guidelines

FDA Opens TRT Pathway for Low Libido in Men (2026)

Specific Claim Evaluated

On April 16, 2026, the FDA announced it would accept supplemental NDAs for testosterone products to treat low libido in men with idiopathic hypogonadism, with a sponsor contact deadline of April 30, 2026.

Primary Research Supporting or Contradicting the Claim

The Federal Register notice invites holders of approved testosterone NDAs to contact the agency regarding a supplemental application for this indication (U.S. Food and Drug Administration, 2026a).

Corrected Evidence-Based Interpretation

Accurate. The announcement opens a pathway; it is not an approval.

Rationale for Grade

The page reports dates and scope correctly and distinguishes the pathway from an approved indication. It acknowledges that online clinics already prescribe off-label for low libido. Despite its commercial setting, the factual content matches the primary notice.

References

  1. U.S. Food and Drug Administration. Potential new indication for testosterone replacement therapy. Federal Register. 2026;91 FR 21002. Document 2026-07615. Published April 20, 2026.
    Supporting excerpt: "information in published literature that seems promising"

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.